Biotechnology

The move gives the unit more independence while preserving support from its parent company.

Executives seek “skin in the game” despite signs of a stock market cooldown.

The listing caps a six-year run with Qiming as one of Alamar’s core venture backers.

It could become the first publicly listed company focused on AI-driven nanodelivery.

The company is preparing multicenter trials as brain-computer interface technology moves closer to clinical deployment.

A new class of PA-targeted drugs promises faster relief, but high prices and uneven access could slow uptake.

Managing partner Shan Fu says the firm can generate stronger returns through its asset-centric accelerator model.

The firm’s share price has nearly tripled over the past year, driven by steady cash flow, global expansion, and a distinct strategy.